Asset
INSULIN DETEMIR
Revenue
No revenue reported in loaded filings.
Clinical trials (64)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05134987 | phase1 | completed | 2021-12-01 | 2022-05-06 | Novo Nordisk A/S | A Multiple Dose Study Investigating Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0363-0845 in Participants With Type 1 Diabetes Pharmacokinetics and Pharmacodynamics: How Insulin NNC0363-0845 is Transported Throughout the Body and How It Works |
| NCT01868542 | phase4 | completed | 2013-06-01 | 2015-05-01 | Novo Nordisk A/S | A Trial Comparing the Glycaemic Control of Levemir® Administered Once Daily According to Two Insulin Detemir Titration Algorithms After 20 Weeks in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Treatment With or Without Other Anti-diabetic Drugs (OADs) |
| NCT01513473 | phase3 | completed | 2012-01-16 | 2013-07-30 | Novo Nordisk A/S | A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus |
| NCT02162407 | phase1 | completed | 1999-10-01 | 1999-12-01 | Novo Nordisk A/S | A Trial Investigating the Relationship Between Pharmacodynamic and Interstitial Concentration for Insulin Detemir and Human Insulin |
| NCT01486966 | phase4 | terminated | 2011-11-01 | 2012-06-01 | Novo Nordisk A/S | Comparing Efficacy and Safety of Insulin Detemir Plus Insulin Aspart and NPH Insulin Plus Human Soluble Insulin With or Without Metformin in Chinese Patients With Type 2 Diabetes |
FDA applications (2)
| Application | Type | Applicant |
|---|---|---|
| BLA 021536 | BLA | Novo Nordisk Inc. |
| BLA 021878 | BLA | NOVO NORDISK |
Marketed products (6)
- LEVEMIR
- LEVEMIR
- LEVEMIR FLEXPEN
- LEVEMIR FLEXTOUCH
- LEVEMIR INNOLET
- LEVEMIR PENFILL